Change in symptom and quality of life in COPD by Budesonide/Glycopyrronium/Formoterol fumarate pressurized metered dose inhaler (BGF pMDI)

Trial Identifier: D5980R00033
Sponsor: AstraZeneca
NCTID:: NCT05219630
Start Date: May 2022
Primary Completion Date: May 2023
Study Completion Date: May 2023
Condition: Chronic Obstructive Pulmonary Disease (COPD)

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Japan, Aichi Nagoya, Aichi, Japan
Japan, Aichi Seto, Aichi, Japan
Japan, Ehime Toon, Ehime, Japan
Japan, Fukui Fukui, Japan
Japan, Fukuoka Fukuoka, Japan
Japan, Fukuoka Kurume, Fukuoka, Japan
Japan, Hiroshima Hiroshima, Japan
Japan, Ibaraki Tsuchiura, Ibaraki, Japan
Japan, Ishikawa Kanazawa, Ishikawa, Japan
Japan, Kagawa Takamatsu, Kagawa, Japan
Japan, Kagoshima Kagoshima, Japan
Japan, Mie Matsusaka, Mie, Japan
Japan, Miyazaki Miyazaki, Japan
Japan, Nara Kashihara, Nara, Japan
Japan, Oita Oita, Japan
Japan, Osaka Osaka, Japan
Japan, Tokyo Chuo, Tokyo, Japan